Paper Details

  1. Home
  2. Paper Details

Faldaprevir and deleobuvir for HCV genotype 1 infection.

Author: AsselahTarik, BourlièreMarc, BronowickiJean-Pierre, ButiMaria, BöcherWulf-Otto, GallivanJohn-Paul, GaneEd J, KukoljGeorge, LohseAnsgar W, MensaFederico J, MüllhauptBeat, RobertsStuart K, SchuchmannMarcus, SorianoVincent, SternJerry O, ViniskoRichard, ZeuzemStefan

Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Faldaprevir in combination with deleobuvir plus ribavirin achieved sustained virologic response rates of 52 to 69% in patients with chronic hepatitis C virus (HCV) genotype 1 infection, demonstrating the potential for interferon-free treatment.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Interferon-free regimens would be a major advance in the treatment of patients with chronic hepatitis C virus (HCV) infection. METHODS: In this phase 2b, randomized, open-label trial of faldaprevir (a protease inhibitor) and deleobuvir (a nonnucleoside polymerase inhibitor), we randomly...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1056/NEJMoa1213557

データ提供：米国国立医学図書館（NLM）

Faldaprevir and Deleobuvir for HCV Genotype 1 Infection: A Promising Interferon-Free Regimen

The vast desert of hepatitis C research is always being explored, with scientists seeking to develop effective and well-tolerated treatments for this chronic viral infection. This study, like a scientific expedition traversing a challenging landscape, investigates the efficacy of faldaprevir and deleobuvir in combination with ribavirin for treating HCV genotype 1 infection. The researchers, like intrepid explorers, conducted a phase 2b randomized trial involving 362 patients. Their findings, like a hidden oasis, suggest that faldaprevir and deleobuvir, in combination with ribavirin, achieve sustained virologic response rates of 52% to 69% in patients with HCV genotype 1 infection. This research, like a beacon of light in the desert, offers a promising interferon-free regimen for treating HCV genotype 1 infection.

Interferon-Free Regimens: A New Dawn in Hepatitis C Treatment

This research, like a compass guiding us towards a brighter future for hepatitis C treatment, underscores the potential of interferon-free regimens. The study, like a carefully crafted map, reveals the promising efficacy of faldaprevir and deleobuvir in combination with ribavirin for treating HCV genotype 1 infection. This research, like a desert spring providing life-giving water, offers hope to patients seeking an effective and well-tolerated treatment option for HCV genotype 1 infection.

Treating Hepatitis C: A Journey Through the Desert of Viral Infections

This research, like a journey through a desert landscape, explores the complexities of hepatitis C treatment and the potential of interferon-free regimens. The authors, like skilled desert guides, carefully navigate the intricate pathways of viral infection, highlighting the promising efficacy of faldaprevir and deleobuvir in combination with ribavirin. This research, like a desert oasis, offers a source of hope and healing for those affected by HCV genotype 1 infection, providing valuable insights into a promising therapeutic approach.

Dr.Camel's Conclusion

This study, like a caravan traversing a vast desert, provides a comprehensive exploration of the efficacy of faldaprevir and deleobuvir in combination with ribavirin for treating HCV genotype 1 infection. The authors, like skilled desert guides, meticulously analyze the data and offer valuable insights into the potential of interferon-free regimens for treating hepatitis C.
Date :
  1. Date Completed 2013-08-29
  2. Date Revised 2022-03-16
Further Info :

Pubmed ID

23944300

DOI: Digital Object Identifier

10.1056/NEJMoa1213557

Related Literature

Article Analysis
・Effective treatment of hepatitis c
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.